Clinical trials are the main way that doctors are able to find better treatment for diseases like cancer. Active clinical trials are exploring possible new cancer treatments and ways to prevent or reduce side effects. In this podcast series, members of the Cancer.Net Editorial Board share their expert opinions about ongoing clinical trials that are studying genitourinary (GU) cancers.

In this podcast, Sumanta (Monty) Pal, MD, leads a discussion with Neeraj Agarwal, MD; Timothy Gilligan, MD, FASCO; and Tian Zhang, MD, about 3 clinical trials in prostate cancer, germ cell tumors, and kidney cancer.

  • The KEYNOTE-641 phase III clinical trial is testing whether adding the immunotherapy pembrolizumab (Keytruda) to the androgen receptor inhibitor enzalutamide (Xtandi) to treat metastatic castration-resistant prostate cancer helps people live longer and delays the progression of the disease. [3:36]

  • The P3BEP phase III clinical trial is observing whether giving chemotherapy more frequently to both adults and children with poor-risk or intermediate-risk metastatic germ cell tumors that didn’t start in the brain cures more patients. [6:38]

  • The PIVOT-09 phase III clinical trial is studying whether treating metastatic kidney cancer with an immunotherapy called bempegaldesleukin in combination with other drugs helps shrink the tumor and helps patients live longer. [11:31]

Dr. Pal is co-director of City of Hope’s Kidney Cancer Program, the head of the kidney and bladder cancer disease team at the institution, and the Cancer.Net Associate Editor for Genitourinary Cancers. Dr. Agarwal directs the Genitourinary Oncology Program at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an assistant professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers.

Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked in the paragraph above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content.